Search Results

You are looking at 101 - 110 of 474 items for :

  • "paclitaxel" x
  • Refine by Access: All x
Clear All
Full access

NCCN Guidelines Updates: Management of Patients With HER2-Negative Breast Cancer

Presented by: William J. Gradishar

and pictilisib, and the dual PI3K/mTOR inhibitor gedatolisib. Initial trials of the AKT inhibitors provided a mixed signal of efficacy. In the phase II PAKT2 trial, capivasertib + paclitaxel improved median OS from 12.6 months to 19.1 months (HR, 0

Full access

Management of Recurrent Small Cell Lung Cancer

Bryan J. Schneider

. Phase III study of oral compared to intravenous topotecan as second-line therapy in small-cell lung cancer . J Clin Oncol 2007 ; 25 : 2086 – 2092 . 14. Dy GK Jett JR Geoffroy FJ . Topotecan and paclitaxel in previously treated patients

Full access

Optimizing Treatment of HER2-Positive Breast Cancer

William J. Gradishar

=.0067) but clinically modest 1.3-month progression-free survival benefit. 9 In the first-line setting of the BOLERO-1/TRIO 019 trial, trastuzumab/paclitaxel/everolimus did not improve progression-free survival overall. However, in the hormone receptor

Full access

Ovarian Cancer, Version 3.2012

Robert J. Morgan, Ronald D. Alvarez, Deborah K. Armstrong, Robert A. Burger, Mariana Castells, Lee-may Chen, Larry Copeland, Marta Ann Crispens, David Gershenson, Heidi Gray, Ardeshir Hakam, Laura J. Havrilesky, Carolyn Johnston, Shashikant Lele, Lainie Martin, Ursula A. Matulonis, David M. O’Malley, Richard T. Penson, Steven W. Remmenga, Paul Sabbatini, Joseph T. Santoso, Russell J. Schilder, Julian Schink, Nelson Teng, Theresa L. Werner, Miranda Hughes, and Mary A. Dwyer

to up-front therapy with carboplatin/paclitaxel or using bevacizumab as maintenance therapy; this disagreement is reflected as a category 3 recommendation. Most panel members believe that bevacizumab should not be added to up-front chemotherapy in

Full access

Novel Non-Cytotoxic Therapy in Ovarian Cancer: Current Status and Future Prospects

Lainie Martin and Russell J. Schilder

trap combined with paclitaxel strikingly inhibits tumor and ascites, prolonging survival in a human ovarian cancer model . Clin Cancer Res 2005 ; 11 ( 19 Pt 1 ): 6966 – 6971 . 30. Eleutherakis-Papaiakovou V Bamias A Dimopoulos MA

Full access

Evolving Treatment Strategies for Triple-Negative Breast Cancer

Melinda Telli

ductal carcinoma who has triple-negative disease and no BRCA1 or BRCA2 mutation identified would be an anthracycline and taxane-based regimen, such as the regimen of dose-dense doxorubicin and cyclophosphamide followed by dose-dense paclitaxel

Full access

Active Systemic Treatment of Pancreatic Cancer

Margaret Tempero

FOLFIRINOX [5-FU, leucovorin, irinotecan, and oxaliplatin] or gemcitabine) and the APACT study (NCT01964430; surgery followed by either gemcitabine/nanoparticle albumin-bound [nab]-paclitaxel or gemcitabine monotherapy). Turning to neoadjuvant therapy, Dr

Full access

Trastuzumab-Related Cardiac Dysfunction

Melinda L. Telli and Ronald M. Witteles

-stage disease settings. After its initial FDA approval in 1998 for first-line treatment of HER2-positive metastatic breast cancer in combination with paclitaxel, a series of pivotal adjuvant studies documented statistically significant improvements in both

Full access

Gastroesophageal Cancers: Progress and Problems

Jaffer A. Ajani

. Kelsey CR Chino JP Willett CG . Paclitaxel-based chemoradiotherapy in the treatment of patients with operable esophageal cancer . Int J Radiat Oncol Biol Phys 2007 ; 69 : 770 – 776 . 12. Javeri H Arora R Correa AM . Influence of induction

Full access

CLO23-062: Pediatric Metastatic Pulmonary Adenocarcinoma

Luke Proctor, Arjith Rathakrishnan, Claudia Zapata, and KanwarAnoop Kainaur

chemotherapy as per Keynote-407 (pembrolizumab, carboplatin and paclitaxel) due to continuous effusions, followed by protocol Keynote-189 (pembrolizumab, cisplatin, pemetrexed). Once his molecular testing revealed an EML4-ALK fusion, he was switched to oral